Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Exclusion Criteria

• •Known loss of complete cytogenetic response (CCyR) by marrow cytogenetic or blood fluorescence in situ hybridization (FISH) for breakpoint cluster region (BCR)- v-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1)
• •Loss of complete hematologic response (CHR)
• •Participation in another clinical trial with any investigative drug within 30 days prior to study enrollment
• •Chronic graft-versus-host disease requiring systemic immunosuppression post-allogeneic hematopoietic stem cell transplantation
• •Cardiovascular disease: history of congestive heart failure, myocardial infarction in the 6 months preceding study entry, symptomatic cardiac arrhythmia requiring treatment
• •History of bladder cancer
• •Gross (visible) hematuria
• •Known history of osteoporosis
• •Known history of macular edema
• •Known history of ABL1-domain mutation that predicts resistance to the discontinued TKI
• •Significant medical or psychiatric disorder that would interfere with consent, study participation, or follow-up
• •Known allergy to pioglitazone
• •Pregnant or breastfeeding
• •Use of thiazolidinedione (TZD) within 28 days prior to enrollment
• •Significant gastrointestinal condition that could potentially impair the absorption or disposition of the drug
• •Uncontrolled peripheral edema (2+ or more) of any etiology
• •Active cancer that requires therapy in the form of chemotherapy or radiation